Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.27 AUD | -.--% | -3.79% | -22.32% |
May. 28 | Private Equity Reportedly Eyes Healius Diagnostic Imaging Unit | CI |
May. 27 | Healius Hires UBS to Sell Lumus Imaging | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Most analysts recommend that the stock should be sold or reduced.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-22.32% | 612M | B- | ||
-24.16% | 7.76B | B+ | ||
+68.65% | 4.33B | C+ | ||
-2.98% | 2.64B | - | ||
+2.72% | 2.63B | B- | ||
-46.17% | 2.16B | B- | ||
-22.12% | 1.46B | A- | ||
+13.62% | 1.17B | B+ | ||
-43.81% | 1.14B | C+ | ||
+20.41% | 999M | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HLS Stock
- Ratings Healius Limited